JP2022542222A5 - - Google Patents
Info
- Publication number
- JP2022542222A5 JP2022542222A5 JP2021578171A JP2021578171A JP2022542222A5 JP 2022542222 A5 JP2022542222 A5 JP 2022542222A5 JP 2021578171 A JP2021578171 A JP 2021578171A JP 2021578171 A JP2021578171 A JP 2021578171A JP 2022542222 A5 JP2022542222 A5 JP 2022542222A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- amino acid
- acid sequence
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910577909.6 | 2019-06-28 | ||
| CN201910577909 | 2019-06-28 | ||
| PCT/CN2020/094767 WO2020259258A1 (zh) | 2019-06-28 | 2020-06-05 | 一种抗体偶联药物、其中间体、制备方法及应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542222A JP2022542222A (ja) | 2022-09-30 |
| JP2022542222A5 true JP2022542222A5 (enExample) | 2023-06-26 |
| JP7407845B2 JP7407845B2 (ja) | 2024-01-04 |
Family
ID=74059658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578171A Active JP7407845B2 (ja) | 2019-06-28 | 2020-06-05 | 抗体薬物複合体、その中間体、製造方法及び使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220233708A1 (enExample) |
| EP (1) | EP3991754A4 (enExample) |
| JP (1) | JP7407845B2 (enExample) |
| KR (1) | KR20220025861A (enExample) |
| CN (1) | CN113766933B (enExample) |
| AU (1) | AU2020301289B2 (enExample) |
| BR (1) | BR112021026580A2 (enExample) |
| CA (1) | CA3144790A1 (enExample) |
| WO (1) | WO2020259258A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230054458A1 (en) * | 2019-12-12 | 2023-02-23 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-claudin antibody-drug conjugate and pharmaceutical use thereof |
| AU2021289927A1 (en) * | 2020-06-08 | 2023-01-19 | Systimmune, Inc. | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
| WO2021252708A1 (en) * | 2020-06-11 | 2021-12-16 | President And Fellows Of Harvard College | Stabilized trioxacarcin antibody drug conjugates and uses thereof |
| JP7753372B2 (ja) * | 2020-10-12 | 2025-10-14 | シーチュアン バイリ ファーム シーオー． エルティーディー | 重水素化カンプトテシン系誘導体及びその抗体薬物複合体 |
| EP4257153B1 (en) * | 2020-12-04 | 2025-11-12 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof |
| CN116583526B (zh) * | 2020-12-11 | 2025-09-26 | 微境生物医药科技(上海)有限公司 | 新型喜树碱衍生物、含其的组合物和其用途 |
| JP7564958B2 (ja) * | 2020-12-18 | 2024-10-09 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | Ｂ７－ｈ３を標的とする抗体薬物複合体、その製造方法と使用 |
| EP4265275A4 (en) * | 2020-12-18 | 2024-03-20 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | ANTIBODY-DRUG CONJUGATE TARGETING TROP2, PREPARATION METHOD AND USE THEREOF |
| CN114805377A (zh) * | 2021-01-29 | 2022-07-29 | 明慧医药（杭州）有限公司 | 适用于抗体-药物偶联物的毒素分子 |
| WO2022171115A1 (zh) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | 用于adc制备的喜树碱衍生物 |
| CN116897149A (zh) * | 2021-03-30 | 2023-10-17 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| CN116867789B (zh) * | 2021-03-31 | 2025-06-24 | 上海复旦张江生物医药股份有限公司 | 一种伊喜替康衍生物的制备方法及其中间体 |
| CN115385926B (zh) * | 2021-05-24 | 2025-06-03 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| IL309457A (en) * | 2021-06-17 | 2024-02-01 | Minghui Pharmaceutical Hangzhou Ltd | Compound against tumors and its use |
| CN117715913A (zh) * | 2021-07-19 | 2024-03-15 | 芝诺管理公司 | 免疫缀合物和方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| WO2023006084A1 (zh) | 2021-07-30 | 2023-02-02 | 上海复旦张江生物医药股份有限公司 | 一种抗dll3抗体及其制备方法、其药物偶联物和应用 |
| MX2024003277A (es) * | 2021-09-15 | 2024-04-04 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia. |
| KR20240082348A (ko) * | 2021-09-27 | 2024-06-10 | 에보포인트 바이오사이언시스 컴퍼니 리미티드 | 항체, 이의 항체-약물 접합체 및 이의 용도 |
| CN118401258A (zh) * | 2021-12-09 | 2024-07-26 | 昆山新蕴达生物科技有限公司 | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 |
| CN119317447A (zh) | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| WO2024008102A1 (en) * | 2022-07-05 | 2024-01-11 | Wuxi Xdc (Shanghai) Co., Ltd. | Linker for conjugation |
| EP4558506A1 (en) * | 2022-07-22 | 2025-05-28 | NJ Bio, Inc. | Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells |
| EP4562051A1 (en) * | 2022-07-26 | 2025-06-04 | Immunome, Inc. | Immunoconjugates and methods |
| JP2025524970A (ja) * | 2022-07-27 | 2025-08-01 | 明慧医藥（杭州）有限公司 | 抗体－薬物コンジュゲートおよびその使用 |
| CN117510515A (zh) * | 2022-07-28 | 2024-02-06 | 明慧医药（杭州）有限公司 | 适用于抗体-药物偶联物的毒素分子 |
| WO2024091437A1 (en) * | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| KR20250111373A (ko) * | 2022-11-25 | 2025-07-22 | 밍훼이 파마슈티컬 (항저우) 리미티드 | 항종양 화합물 및 이의 응용 |
| WO2024114667A1 (zh) * | 2022-11-30 | 2024-06-06 | 正大天晴药业集团股份有限公司 | 抗cldn18.2抗体药物偶联物及其药物组合物和用途 |
| CN116178386B (zh) | 2022-12-30 | 2025-09-09 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| CN116217655B (zh) * | 2022-12-30 | 2025-09-23 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的中间体的制备方法 |
| CN116217654B (zh) * | 2022-12-30 | 2025-09-26 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| JPWO2024214685A1 (enExample) | 2023-04-10 | 2024-10-17 | ||
| WO2025021152A1 (zh) * | 2023-07-26 | 2025-01-30 | 上海医药集团股份有限公司 | 喜树碱类小分子及其抗体药物偶联物、制备方法和应用 |
| WO2025049270A1 (en) * | 2023-08-25 | 2025-03-06 | Macrogenics, Inc. | B7-h3 antibody-drug conjugates |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2025238587A1 (en) | 2024-05-16 | 2025-11-20 | Daiichi Sankyo Company, Limited | Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor |
| CN120617538B (zh) * | 2025-07-21 | 2026-04-03 | 南京滴力生物科技有限公司 | 一种用于治疗肿瘤的抗体药物偶联物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2240495B1 (en) * | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| NZ610239A (en) * | 2008-04-30 | 2014-11-28 | Immunogen Inc | Cross-linkers and their uses |
| ES2647317T3 (es) * | 2008-11-03 | 2017-12-20 | Syntarga B.V. | Análogos de CC-1065 y sus conjugados |
| WO2013173337A2 (en) * | 2012-05-15 | 2013-11-21 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| ES2773710T3 (es) * | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| IL310627B2 (en) * | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| EP3209334A2 (en) * | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| EP4321523A3 (en) * | 2017-08-10 | 2024-04-24 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivatives and antibody-drug conjugates including same |
| WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| WO2019034177A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
| CN109200291B (zh) * | 2018-10-24 | 2021-06-08 | 中国医学科学院医药生物技术研究所 | 一种靶向于egfr的抗体偶联药物及其制备方法和其用途 |
-
2020
- 2020-06-05 CN CN202080030918.4A patent/CN113766933B/zh active Active
- 2020-06-05 AU AU2020301289A patent/AU2020301289B2/en active Active
- 2020-06-05 BR BR112021026580A patent/BR112021026580A2/pt unknown
- 2020-06-05 CA CA3144790A patent/CA3144790A1/en active Pending
- 2020-06-05 US US17/622,500 patent/US20220233708A1/en active Pending
- 2020-06-05 JP JP2021578171A patent/JP7407845B2/ja active Active
- 2020-06-05 EP EP20833007.6A patent/EP3991754A4/en active Pending
- 2020-06-05 KR KR1020227002873A patent/KR20220025861A/ko active Pending
- 2020-06-05 WO PCT/CN2020/094767 patent/WO2020259258A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542222A5 (enExample) | ||
| TWI868726B (zh) | 抗體-藥物結合物之新穎製造方法 | |
| JP7754361B2 (ja) | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | |
| JP2023510905A5 (enExample) | ||
| JPWO2020122034A5 (enExample) | ||
| CN112261954A (zh) | 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐 | |
| JP2022532918A5 (enExample) | ||
| CN113194983A (zh) | 用于治疗病毒感染的组合物及方法 | |
| CN1045089C (zh) | 2－(2－氨基－1,6－二氢－6－氧代－嘌呤－9－基)甲氧基－1,3－丙二醇衍生物 | |
| JP2013500304A5 (enExample) | ||
| WO2022199237A1 (zh) | 修饰的氨基酸及其在adc中的应用 | |
| JP2022507781A5 (enExample) | ||
| JP2023519261A5 (enExample) | ||
| JP2024546497A5 (enExample) | ||
| JP2025503493A5 (enExample) | ||
| WO2024130161A2 (en) | Novel camptothecin derivatives and conjugates thereof | |
| JP2024088768A5 (enExample) | ||
| AU2022234694A9 (en) | Compound or salt thereof, and antibody obtained using same | |
| BR112021001992A2 (pt) | efeito adjuvante do agonista tlr1/2 diprovocim sinergiza com anticorpos inibidores de checkpoint para eliminar doença | |
| JP2025124732A (ja) | 化合物またはその塩、およびそれらにより得られる抗体 | |
| JP2019524845A5 (enExample) | ||
| WO2024119049A1 (en) | Compositions and methods for protein internalization | |
| TWI820038B (zh) | 妥布賴森(tubulysins)及其中間產物之製備方法 | |
| TWI825169B (zh) | 妥布賴森(tubulysins)及其中間體之製備之替代方法 | |
| WO2019168164A1 (ja) | タンパク質及び／又はペプチド修飾用分子 |